Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS Mutant Status May Be Associated with Distant Recurrence in Early-stage Rectal Cancer.

Anticancer research - 1 Mar 2017

Sideris Michail, Moorhead Jane, Diaz-Cano Salvador, Haji Amyn, Papagrigoriadis Savvas

Abstract excerpt

BACKGROUND/AIM: Total mesorectal excision combined with neo-adjuvant chemoradiotherary (CRT) and adjuvant chemotherapy, has been the standard treatment of locally advanced rectal cancer (LARC). Although TNM (Tumor, Node, Metastasis) classification for malignant Tumors is still the cornerstone in rectal cancer staging, there has been an effort to identify molecular biomarkers with additional prognostic or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Genes, ras
Share to Multivariate Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Predictive Value of Tests

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Share to Rectal Neoplasms

Source

Identifiers

PMID: 28314302
DOI: 10.21873/anticanres.11454

Genes

KRAS
BRAF
MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS Mutant Status May Be Associated with Distant Recurrence in Early-stage Rectal Cancer.PMID 28314302Read ↗

KRAS Mutant Status, p16 and β-catenin Expression May Predict Local Recurrence in Patients Who Underwent Transanal Endoscopic Microsurgery (TEMS) for Stage I Rectal Cancer.Semantic proximity Read ↗

Impact of RAS/BRAF mutation status in locally advanced rectal cancer treated with preoperative chemotherapy.Semantic proximity Read ↗

Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer.Semantic proximity Read ↗

The prognostic value of KRAS mutation in locally advanced rectal cancer.Semantic proximity Read ↗

Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery.Semantic proximity Read ↗

The prognostic value of KRAS mutation in locally advanced rectal cancer.Semantic proximity Read ↗

RAS Mutations Predict Recurrence-Free Survival and Recurrence Patterns in Colon Cancer: A Unicenter Study in Morocco.Semantic proximity Read ↗

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.Semantic proximity Read ↗

Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer.Semantic proximity Read ↗

KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis.Semantic proximity Read ↗

Negative prognostic impact of Co-mutations in TGFβ and TP53 pathways in surgically resected rectal tumors following neoadjuvant chemoradiotherapy.Semantic proximity Read ↗

Tumor mutation burden in blood predicts benefit from neoadjuvant chemo/radiotherapy in locally advanced rectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.